<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Investors Business Daily</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.investors.com/news/technology/novartis-stock-novartis-earnings-q2-2026/">Novartis Bounds For Buy Point. Why Shares Are On The Rise.</a>
    </div>

      <div class="me-0 me-md-5">
        Novartis stock jumped early Tuesday on better-than-expected second-quarter metrics, partially driven by Cosentyx.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-ceo-vas-narasimhan-says-no-change-plans-2026-07-21/">Novartis CEO Vas Narasimhan says &#39;no change of plans&#39;</a>
    </div>

      <div class="me-0 me-md-5">
        Novartis chief executive ​officer Vas Narasimhan ‌said on Tuesday he plans ​to stick ​around for the Swiss ⁠drugmaker&#39;s next ​phase of growth, ​ahead of a series of high-stakes trial ​data expected ​for the company in ‌the ⁠second half of the year.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-danger bg-red-100">
          Negative
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Invezz</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://invezz.com/news/2026/07/21/novartis-q2-surpasses-estimates-despite-50-entresto-sales-drop/?utm_source=snapi">Novartis Q2 surpasses estimates despite 50% Entresto sales drop</a>
    </div>

      <div class="me-0 me-md-5">
        Novartis beat market expectations for second-quarter core operating profit on Tuesday. Lower-than-expected costs helped the Swiss drugmaker offset a sharp decline in sales of its top-selling heart failure drug Entresto.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/business/earnings/novartis-returns-to-growth-on-sales-momentum-from-key-drugs-e988f92a">Novartis Returns to Growth on Sales Momentum From Key Drugs</a>
    </div>

      <div class="me-0 me-md-5">
        Second-quarter net sales rose 1% at constant currency as growth from some of its top-selling products offset declines for medicines that lost patent protection.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-q2-profit-up-generic-competition-mounts-2026-07-21/">Novartis Q2 profit up as generic competition mounts</a>
    </div>

      <div class="me-0 me-md-5">
        Novartis&#39; second-quarter core operating profit beat ​market expectations on Tuesday, ‌helped by strong sales of cancer and ​multiple sclerosis drugs.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/novartis-faces-drug-pipeline-test-with-valuation-premium-focus-2026-07-20/">Novartis faces drug pipeline test with valuation premium in focus</a>
    </div>

      <div class="me-0 me-md-5">
        Novartis investors will look beyond Tuesday&#39;s quarterly results for indications about three major drug trial readouts due in ‌the second half of the year seen as vital to justifying the Swiss drugmaker&#39;s premium valuation.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">WSJ</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.wsj.com/health/pharma/novartis-to-buy-myricx-bio-for-up-to-1-5-billion-6e8ee865">Novartis to Buy Myricx Bio for Up to $1.5 Billion</a>
    </div>

      <div class="me-0 me-md-5">
        The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis&#39;s oncology capabilities.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Novartis-ADR-US66987V1098">Novartis ADR</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">3 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/legal/litigation/novartis-acquire-uk-based-myricx-bio-up-15-billion-2026-07-06/">Novartis to acquire UK-based Myricx Bio for up to $1.5 billion</a>
    </div>

      <div class="me-0 me-md-5">
        Swiss drugmaker Novartis said on Monday it had ​agreed to pay up to $1.5 ‌billion for U.K.-based biotechnology firm Myricx Bio in a deal expected ​to close in the second ​half of 2026.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/Novartis-ADR-US66987V1098/load_more?page=8">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>